Inventor · disambiguated record
Christopher F. Bender
Also filed as: BENDER CHRISTOPHER F
17 granted patents·5 pending applications·195 citations·filing 2012–2025
94Inventor score
Top patents by PatentIndex Score
22 records- 0197US10398711B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2018·Granted Sep 3, 2019·15 cites·10 claims
- 0297US9889143B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2016·Granted Feb 13, 2018·19 cites·23 claims
- 0396US9512094B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2014·Granted Dec 6, 2016·22 cites·11 claims
- 0495US9556222B2A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Jan 31, 2017·21 cites·19 claims
- 0594US9290536B2C4 monomethyl triterpenoid derivatives and methods of use thereofANDERSON ERIC·Filed 2012·Granted Mar 22, 2016·32 cites·27 claims
- 0693US9278912B2C13-hydroxy derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Mar 8, 2016·30 cites·24 claims
- 0792US10501489B2C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2017·Granted Dec 10, 2019·12 cites·15 claims
- 0892US9464082B2Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulatorsABBVIE INC·Filed 2015·Granted Oct 11, 2016·18 cites·24 claims
- 0991US9593074B2C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Mar 14, 2017·17 cites·30 claims
- 1090US10898499B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2019·Granted Jan 26, 2021·2 cites·25 claims
- 1187US11406648B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·1 cites·19 claims
- 1287US11292781B2Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other usesREATA PHARMACEUTICALS INC·Filed 2017·Granted Apr 5, 2022·4 cites·40 claims
- 1384US11827664B2Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathwayREATA PHARMACEUTICALS INC·Filed 2019·Granted Nov 28, 2023·1 cites·17 claims
- 1479US2025188053A1Pyrimidine tricyclic enone derivatives for inhibition of ror-gamma and other usesREATA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1571US2024360084A1Pyrazole and imidazole compounds for inhibition of il-17 and rorgammaREATA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1670US12195443B2Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other usesREATA PHARMACEUTICALS INC·Filed 2022·Granted Jan 14, 2025·0 cites·35 claims
- 1769US11059792B2Imidazolyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2016·Granted Jul 13, 2021·1 cites·9 claims
- 1867US2025361263A1C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1962US12344631B2C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2020·Granted Jul 1, 2025·0 cites·9 claims
- 2054US11993574B2Pyrazole and imidazole compounds for inhibition of IL-17 and RORgammaREATA PHARMACEUTICALS INC·Filed 2019·Granted May 28, 2024·0 cites·37 claims
- 2149US2023111914A1Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2243US2014088163A1C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher F. Bender files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →